Pharmaceutical Technology

MAY 19, 2023

MT-302 is a TROP2-targeting in vivo chimeric antigen receptor (CAR) that has been designed to express in the myeloid compartment. The financing will help to fast-track the development of other in vivo programming candidates into clinical trials. Topic sponsors are not involved in the creation of editorial content.

Gene Therapy 244

Gene Therapy In-Vivo Gene Clinical Trials 244

Bio Pharma Dive

FEBRUARY 22, 2023

The messenger RNA specialist said Wednesday it is teaming up with Life Edit Therapeutics to develop therapies that can modify genes “in vivo.”

Gene Editing 264

Gene Editing Gene In-Vivo RNA 264

Drug Discovery World

SEPTEMBER 14, 2022

The post The latest MHC class I & II deficient in vivo platform humanised with PBMCs appeared first on Drug Discovery World (DDW). How this platform can support a wide range of immunological studies, especially those containing T cells responses. The versatility of this platform to various research disciplines.

In-Vivo 52

In-Vivo Drugs Containment Research 52

Drug Discovery World

SEPTEMBER 14, 2022

Hu-PBMC mice are used as in vivo models to study and evaluate compounds for T cell immune modulation, infectious diseases and graft rejection research. The post The latest MHC class I & II deficient in vivo platform humanised with PBMCs appeared first on Drug Discovery World (DDW). Download here.

In-Vivo 52

In-Vivo Drugs Containment Research 52

Scienmag

SEPTEMBER 28, 2020

CIC biomaGUNE researchers have demonstrated the restoring in vivo of the connection between neurons, yielding functional results Credit: Author: Pedro Ramos / CIC biomaGUNE Research conducted by two groups at the Center for Cooperative Research in Biomaterials CIC biomaGUNE and one at SISSA, Scuola Internazionale Superiore di Studi Avanzati (Italy), (..)

In-Vivo 96

In-Vivo Research Medicine Engineer 96

Bio Pharma Dive

NOVEMBER 29, 2022

In this continuing series, BioPharma Dive examines new areas of biotech investment and startup activity, such as next-generation RNA medicines, TYK2 inhibitors and in vivo CAR-T.

In-Vivo 240

In-Vivo RNA Medicine Research 240

Pharmaceutical Technology

APRIL 14, 2023

All the new GD2 CAR designs developed through the partnership will be validated via in vitro screens and in vivo murine models. All the new GD2 CAR designs developed through the partnership will be validated via in vitro screens and in vivo murine models. Topic sponsors are not involved in the creation of editorial content.

Gene Therapy 264

Gene Therapy In-Vivo In-Vitro Gene 264

Pharmaceutical Technology

MAY 17, 2023

Scribe Therapeutics has entered a strategic collaboration with Eli Lilly and Company subsidiary Prevail Therapeutics for accelerating in vivo CRISPR-based therapies to target the causes of serious neurological and neuromuscular diseases. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Genetics 130

Genetics Medicine Gene Therapy In-Vivo 130

Pharmaceutical Technology

MAY 12, 2023

The in vivo study, conducted in mice, involved a phosphatidylserine-containing nano-formulation of mRNA supplied by BioNTech, distinct from traditional lipid nanocrystals (LNCs). The latter partnership was recently expanded to focus on in vitro and in vivo delivery of mRNA after BioNTech pulled out of the deal with Matinas.

Vaccination 130

Vaccination Vaccine Gene Therapy In-Vivo 130

Pharmaceutical Technology

MAY 16, 2023

In preclinical trials, NXP900 showed significant single-agent antitumour activity in various in vivo xenograft models, including in squamous cell cancers such as cervical, head and neck and oesophageal carcinomas where hippo pathway mutations and copy number abnormalities are predominant.

In-Vivo 130

In-Vivo In-Vitro Clinical Trials Clinical Trials 130

BioTech 365

NOVEMBER 9, 2020

LIfT BioSciences N-LIfT Cell Therapy Successfully Infiltrates Pancreatic Tumours In-vivo LIfT BioSciences N-LIfT Cell Therapy Successfully Infiltrates Pancreatic Tumours In-vivo LIfT BioSciences N-LIfT Cell Therapy Successfully Infiltrates Pancreatic Tumours In-vivo London, 9 November 2020 ­–LIfT BioSciences, a biotech company developing (..)

In-Vivo 52

In-Vivo Development 52

Bio Pharma Dive

NOVEMBER 11, 2020

The biotech won a grant from the foundation two days after dosing the first patient in a study of an in vivo CRISPR medicine, a milestone for the company and the technology.

In-Vivo 364

In-Vivo Medicine 364

Scienmag

AUGUST 12, 2020

Researchers in China have taken the first step towards a new way of treating gastric wounds by using a microrobot combined with the new concept of “in situ in vivo bioprinting” to carry out tissue repair inside the body.

In-Vivo 72

In-Vivo Research Medicine Engineer 72

Medical Xpress

MAY 16, 2023

That was the case when Thilini Gamage was to carry out one of the studies in her doctoral work with Professor Eirik Frengen at the Institute of Clinical Medicine, University of Oslo. They study gene variation and mutations that cause rare genetic diseases. A mutation is a permanent change in the genetic material.

In-Vitro 98

In-Vitro Genetic Disease In-Vivo Genetics 98

Pharmaceutical Technology

MARCH 16, 2023

The partnership will use nanotechnology, which was proven in vivo, for providing antibodies inside tumour cells and provides a potential solution to address the medical challenge. The nanocapsules are designed specifically around the antibodies’ physicochemical properties, for protecting them from degradation in the bloodstream.

Antibody 262

Antibody In-Vivo Pharma Companies Protein 262

Pharmaceutical Technology

FEBRUARY 23, 2023

Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. Our novel editing systems have the potential to precisely modify gene targets for both in vivo and ex vivo therapeutic development.”

Gene Editing 147

Gene Editing Gene Gene Therapy In-Vivo 147

Pharmaceutical Technology

MAY 31, 2023

In vivo and in vitro pre-clinical studies demonstrated that CFT8919 provides wider coverage of on-target resistant mutations and intracranial activity, indicating its potential to be effective against brain metastases. The agreement will cover the Hong Kong special administrative region (SAR), the Macau SAR and Taiwan.

Bioavailability 130

Bioavailability In-Vitro In-Vivo Clinical Development 130

Scienmag

SEPTEMBER 29, 2021

Furthermore, the current understanding of beta cell function is mostly derived from studies of ex vivo isolated islets in rodent […]. However, the highly regulated process of insulin secretion, especially its molecular features and the stimuli behind this process have not yet been fully understood.

In-Vivo 52

In-Vivo Insulin Research Development 52

BioTech 365

OCTOBER 25, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Intellia, LogicBio fuel hope for in vivo gene editing with new animal data in rare diseases: report.Intellia, LogicBio fuel hope for in vivo gene editing with new … Continue reading →

Gene Editing 40

Gene Editing In-Vivo Gene Research 40

BioTech 365

AUGUST 25, 2021

Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021 Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021 DURHAM, N.C.–(BUSINESS –(BUSINESS WIRE)–Precision BioSciences, Inc.

Gene Editing 40

Gene Editing In-Vivo Gene 40

Medical Xpress

MAY 15, 2023

A new research paper, titled "In vitro and in vivo effects of zoledronic acid on senescence and senescence-associated secretory phenotype markers," was published on the cover of Aging

In-Vitro 98

In-Vitro In-Vivo Research 98

BioTech 365

DECEMBER 3, 2021

CAMP4 Presents In Vivo Data Supporting Novel Therapeutic Strategy for Dravet Syndrome at American Epilepsy Society Annual Meeting CAMP4 Presents In Vivo Data Supporting Novel Therapeutic Strategy for Dravet Syndrome at American Epilepsy Society Annual Meeting – Upregulation of SCN1A … Continue reading →

In-Vivo 52

In-Vivo 52

BioTech 365

MAY 26, 2021

Biomedical Microelectromechanical Systems Markets: In Vivo Devices and Microcantilever Sensors – Global Forecast to 2025 – ResearchAndMarkets.com Biomedical Microelectromechanical Systems Markets: In Vivo Devices and Microcantilever Sensors – Global Forecast to 2025 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The (..)

In-Vivo 40

In-Vivo Marketing 40

Pharmaceutical Technology

MAY 5, 2023

TFF Pharmaceuticals and NIEHS will investigate the TFF-HMW-HA formulations’ therapeutic efficacy and pharmacokinetics using in vitro and in vivo models of respiratory diseases.

In-Vivo 162

In-Vivo In-Vitro Development Drugs 162

BioTech 365

APRIL 8, 2021

Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor CAMBRIDGE, Mass.–(BUSINESS

In-Vivo 52

In-Vivo Medicine 52

Pharmaceutical Technology

MAY 23, 2023

Alongside this, the funding will also be used to fuel the Quanta’s RAF1 discovery program where oral small molecule candidates have displayed in-vivo proof-of-concept activity, per the May 22 announcement. Quanta Therapeutics has raised $50.7 billion in 2029. GlobalData is the parent company of Pharmaceutical Technology.

In-Vivo 130

In-Vivo Research Gene Sales 130

Pharmaceutical Technology

NOVEMBER 22, 2022

In June last year, the company raised Series B funds worth $210m to advance its pipeline of in vivo engineered CAR T cell immunotherapies for treating solid tumours and hematologic malignancies into the clinic. In the initial stage, the partnership will focus on acute myeloid leukaemia (AML) to boost accessibility to patients.

In-Vivo 276

In-Vivo Development Clinical Trials Clinical Trials 276

Pharmaceutical Technology

MARCH 29, 2023

In vivo data to date suggests therapeutic plasma levels of VK2735 may be achieved via oral dosing. The company hopes for results to be available in the second half of 2023. The Phase I study is an extension of a previously completed Phase I trial that evaluated the subcutaneous administration of VK2735.

Drugs 264

Drugs In-Vivo Trials Marketing 264

BioTech 365

DECEMBER 23, 2021

Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System Orthogonal IL-2 … Continue reading →

In-Vivo 52

In-Vivo 52

Pharmaceutical Technology

APRIL 13, 2023

Significant collaborative R&D programmes that are likely to be affected include Takeda’s partnership with Codexis for AAV-based gene therapy for Fabry disease and Takeda’s $3.6bn dollar deal with Poseida for the development of nonviral in vivo gene therapy programmes for the hereditary bleeding disorder haemophilia A.

Gene Therapy 243

Gene Therapy Gene In-Vivo Marketing 243

BioTech 365

JANUARY 10, 2022

Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a … Continue reading →

In-Vivo 52

In-Vivo Research 52

BioTech 365

AUGUST 31, 2021

Ixaka to present in vivo gene delivery platform for CAR-T and related bioproduction challenges at 6th CAR TCR Summit Ixaka to present in vivo gene delivery platform for CAR-T and related bioproduction challenges at 6th CAR TCR Summit CSO, Cecile … Continue reading →

In-Vivo 52

In-Vivo Gene 52

Drug Discovery World

APRIL 18, 2023

Comparison to Velcade In a head-to-head study, AVA2727D killed cancers cells (ex-vivo) as effectively as bortezomib (Takeda’s Velcade) which is one of the approved proteasome inhibitors on the market. Proteasome inhibitors are effective anti-cancer drugs that could benefit from application of our preICISION technology to expand their use.

In-Vivo 97

In-Vivo Clinical Development Drugs Development 97

Pharmaceutical Technology

NOVEMBER 9, 2022

The collaboration project will evaluate the tumoricidal effects in an orthotopic mouse model and the advantages of LB-1 in-vivo nanoparticle-based administration. The collaboration project will evaluate the tumoricidal effects in an orthotopic mouse model and the advantages of LB-1 in-vivo nanoparticle-based administration.

In-Vivo 130

In-Vivo In-Vitro Development Scientist 130

BioTech 365

APRIL 12, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sanofi pays $160M for mRNA tech to reprogram T cells in vivo.Sanofi pays $160M for mRNA tech to reprogram T cells in vivo ntaylor Mon, 04/12/2021 – … Continue reading →

In-Vivo 40

In-Vivo Research 40

Pharmaceutical Technology

JANUARY 4, 2023

A synergistic activity was also observed between the anti-Gremlin1 antibody and enzalutamide against castration-resistant prostate cancer models derived from patients in vitro and in vivo. TST003 is a first-in-class Gremlin1 targeting humanised monoclonal antibody.

Antibody 242

Antibody In-Vitro In-Vivo Drugs 242

Pharmaceutical Technology

FEBRUARY 15, 2023

Developing both in vivo and ex vivo gene editing medicines, Editas Medicine is primarily involved in the haematology and oncology therapy areas. However, not all innovations are equal and nor do they follow a constant upward trend. Editas Medicine is one of the most important players concerning innovation surrounding CRISPR nucleases.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162